Orladeyo (Berotralstat)

Berotralstat works by reversibly inhibiting plasma kallikrein, the enzyme responsible for generating bradykinin. Reduced bradykinin levels lower vascular permeability, which in turn prevents the sudden swelling characteristic of hereditary angioedema attacks.

The specific dose of Orladeyo is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. The prescriber will provide individualized dosing instructions and any necessary adjustments.

Safety data for berotralstat in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Orladeyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Orladeyo (berotralstat) is an oral plasma kallikrein inhibitor, offering a convenient daily tablet compared with injectable options such as C1‑esterase inhibitor concentrates or monoclonal antibodies like lanadelumab. While injectables provide rapid onset, the oral route may improve adherence for patients preferring non‑invasive therapy.

Orladeyo tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Orladeyo is taken orally as a whole tablet with water. The prescriber will advise whether it should be taken with or without food, and patients should follow the exact timing and frequency recommended to maintain consistent drug levels.

Serious, though rare, risks include anaphylaxis, severe allergic reactions, paradoxical angioedema, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or signs of liver dysfunction.

Orladeyo is contraindicated in individuals with known hypersensitivity to berotralstat or any tablet excipients. Patients with severe hepatic impairment should avoid use, and those taking medications that strongly interact with CYP3A4 should be evaluated carefully by their healthcare provider.